Sara Cox
Family Medicine · Elwood, INNPI 1922020288
Payments from drug & device makers
Across 363 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$870
- AbbVie$727
- Pfizer$578
- Lilly USA, LLC$554
- Dexcom, Inc.$399
- Bayer$399
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,683100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $870 |
| AbbVie | 61 | $727 |
| Pfizer | 43 | $578 |
| Lilly USA, LLC | 42 | $554 |
| Dexcom, Inc. | 20 | $399 |
| Bayer | 23 | $399 |
| Boehringer Ingelheim | 18 | $305 |
| Novo Nordisk | 22 | $283 |
| Amgen | 10 | $201 |
| Exact Sciences | 11 | $193 |
| GSK | 8 | $120 |
| Astellas Pharma US Inc | 6 | $104 |
| Sanofi-aventis U.S. LLC | 7 | $92 |
| E.r. Squibb & Sons, L.L.C. | 6 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Abbott | 3 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $60 |
| Johnson & Johnson | 3 | $51 |
| Corcept Therapeutics | 2 | $41 |
| Lundbeck LLC | 1 | $35 |
| Ascensia Diabetes Care US Inc. | 1 | $32 |
| Novartis | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Tonix Medicines, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Merck | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
How this compares
$5,691 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $131,620 |
| OzempicSemaglutide | 111 | $130,609 |
| TrulicityDulaglutide | 34 | $71,729 |
| EliquisApixaban | 73 | $64,545 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $27,447 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $20,095 |
| MounjaroTirzepatide | 15 | $17,442 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 49 | $15,515 |
| EntrestoSacubitril/Valsartan | 16 | $13,975 |
| TradjentaLinagliptin | 24 | $12,392 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $9,963 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 44 | $9,687 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $8,854 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,598 |
| FarxigaDapagliflozin Propanediol | 13 | $8,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Combivent Respimat, Spiriva Respimat | $305 | $182,405223 claims |
| Novo NordiskOzempic | $283 | $130,609111 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $554 | $89,17149 claims |
| PfizerEliquis, Abrysvo | $578 | $80,060122 claims |
| GSKTrelegy Ellipta, Shingrix, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $120 | $56,345129 claims |
| NovartisEntresto | $26 | $13,97516 claims |
| AstraZenecaFarxiga | $870 | $8,55813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Elwood
- Steven GatewoodElwood$281K
- Robert HelmElwood$44K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.